How Foreign Investors Can Enter Indonesia's Life Science Market: A Practical Look at the Rules

A recent industry report from this desk outlined why Indonesia's life science sector — spanning biodiversity-based research, regenerative medicine, functional nutrition, and cosmeceuticals — is drawing renewed attention from international investors. The follow-up question from several readers was more practical: how does a foreign company actually get in? What legal structure is required, what does the regulatory pathway look like for regulated products, and where do foreign investors typically get stuck?

The good news is that Indonesia's foreign investment framework has become meaningfully more accessible over the past year. The more nuanced news is that market access and operational execution are two different things — and in a regulated sector like life sciences, the gap between the two is where most foreign entrants lose time and money.

The Legal Entry Point: PT PMA

Any foreign individual or company seeking to hold equity, generate revenue, or obtain operating licenses in Indonesia must do so through a PT PMA (Penanaman Modal Asing) — Indonesia's foreign-owned limited liability company structure. Under Minister of Investment Regulation No. 5 of 2025, effective since October 2025, the minimum paid-up capital for a PT PMA was reduced from IDR 10 billion to IDR 2.5 billion (roughly US$150,000), while the broader investment plan for the business activity must still exceed IDR 10 billion, excluding land and buildings.

Registration runs through Indonesia's OSS-RBA (Online Single Submission, Risk-Based Approach) system and typically takes three to six weeks, requiring at least two shareholders, one director, one commissioner, and a registered Indonesian business address.

The Regulatory Track for Regenerative Medicine

For investors specifically eyeing regenerative medicine, the regulatory picture has become considerably clearer. In 2025, BPOM (Indonesia's food and drug authority) issued Regulation No. 8/2025, formally establishing assessment guidelines for Advanced Therapy Medicinal Products (ATMP) — covering stem cell, gene, and tissue-based therapies.

Speaking in Jakarta in July 2026, BPOM's leadership set out an explicit ambition for Indonesia to become an Asia-Pacific hub for ATMP, citing five GMP-certified stem cell facilities already operating nationwide, regulatory mentorship extended to 43 more, and active collaboration with 186 universities and 270 GMP-certified pharmaceutical facilities.

The scale of the opportunity behind that ambition is significant: the global ATMP market is projected to more than double, from roughly US$41.5 billion in 2026 to US$86.8 billion by 2031. Indonesia is now actively positioning its regulatory framework — and its GMP-certified facility network — to capture a share of that growth, rather than remain a downstream consumer of therapies developed elsewhere.

Where Foreign Investors Typically Get Stuck

In practice, the friction points for foreign life science investors tend to cluster around a few recurring issues:

• KBLI classification — choosing the wrong business classification code can restrict foreign ownership, complicate licensing, or require restructuring later.
• Regulatory navigation — securing BPOM approval for a regulated product or therapy requires familiarity with an evolving framework, not just the published regulation text.
• GMP infrastructure — building or accessing a compliant laboratory from scratch is capital- and time-intensive; most foreign entrants underestimate the timeline.
• Distribution access — Indonesia's clinic and hospital network is large and fragmented; reaching it without existing relationships is slow.
• Local structuring — regulated sub-sectors often benefit from, or require, an established domestic entity as a co-pilot rather than a foreign entity operating alone.

Where a Local Partner Changes the Timeline

None of the friction points above are unusual for a market this size — they are the normal cost of entering a large, regulated, fast-evolving system. What changes the equation is whether a foreign investor is solving them from zero, or alongside a partner who already has the classification experience, regulatory relationships, laboratory know-how, and distribution network in place.

This is the role SciencePreneur plays for foreign companies entering Indonesia's life science market. As an integrated sciencepreneurship platform anchored by PT Sciencepreneur Indonesia Gemilang, an Indonesian-capital (PMDN) life science company, SciencePreneur connects scientific experts, industry, and communities through consultation, commercialization support, and a curated marketplace for science-based products and services. Its own portfolio — spanning natural product and biodiversity research through INPL, a public biodiversity database through CitMed, stem cell and secretome product distribution to clinics and hospitals, GMP laboratory development and budget planning, and ATMP education programs built with clinical partners — reflects the exact execution layer most foreign investors are missing on entry.

For international investors, the practical takeaway is straightforward: Indonesia's legal door to entry is now wider than it has been in years, and the regulatory pathway for regenerative medicine is clearer than it has ever been. What still determines how fast — and how successfully — a foreign company can operate is who it partners with on the ground.

Open for Partnership

SciencePreneur is open to partnership, joint ventures, and collaboration discussions with international investors, laboratories, and life science companies exploring entry into the Indonesian market — from KBLI and regulatory navigation to lab development, distribution, and product commercialization.

Next in this series: Indonesia's Biodiversity Data Gap →